Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Press Releases

SAN DIEGO – January 2, 2018 – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that Scott Struthers, Ph.D., founder and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 11:30 a.m. PT. The conference is…

read more

Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly

Press Releases

SAN DIEGO – October 26, 2017 – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the initiation of a Phase 1, double-blind, randomized, placebo-controlled, single- and-multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CRN00808 in healthy volunteers. CRN00808 is a nonpeptide somatostatin agonist designed…

read more

Crinetics Pharmaceuticals Awarded Two SBIR Grants to Develop New Therapeutics for Congenital Hyperinsulinism and Cushing’s Disease

Press Releases

SAN DIEGO – September 6, 2017 – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that it was awarded two new grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) that could total $2.4 million….

read more

Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808

Press Releases

SAN DIEGO – July 13, 2017 – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that it was awarded a Phase IIB Small Business Innovation Research (SBIR) grant of up to $2.8 million from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of…

read more

Crinetics Pharmaceuticals Appoints Ajay Madan as Vice President, Development

Press Releases

SAN DIEGO – June 6, 2016 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on specialty endocrine disorders, announced today the addition of Ajay Madan, Ph.D., D.A.B.T. as Vice President, Development. “We continue to strategically assemble a world-class team with deep expertise in discovering and developing innovative therapeutics,” said Scott Struthers, Ph.D., Founder and…

read more

Crinetics Pharmaceuticals Completes $40 Million Series A Financing

Press Releases

SAN DIEGO – November 2, 2015 – Crinetics Pharmaceuticals, an innovative therapeutics company focused on specialty endocrine disorders, announced today the completion of a $40 million series A financing led by 5AM Ventures, Versant Ventures, and Vivo Capital. Crinetics plans to use the proceeds to advance development of its small molecule somatostatin agonist program to…

read more

Crinetics Pharmaceuticals Appoints Matt Fust, M.B.A., David Clemons, M.D., and John Wallen, Ph.D., J.D. as Corporate, Clinical, and Legal Advisers

Press Releases

SAN DIEGO – April 27, 2015 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on endocrine diseases and cancers, announced today the addition of corporate, clinical, and legal advisers as the company prepares for the clinical development of its pipeline of first- and best-in-class medicines. Matt Fust will serve as a corporate adviser. Mr….

read more

Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain

Press Releases

SAN DIEGO – April 27, 2015 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on endocrine diseases and cancers, announced today that it has been awarded Phase I of a Fast-Track Small Business Innovation Research (SBIR) grant of up to $2.7MM from the National Institute of Neurological Disorders and Stroke (NINDS) of the National…

read more